Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates

Mass General Brigham

Status and phase

Completed

Phase 2

Conditions

Multiple Myeloma

Treatments

Drug: Zoledronic acid

Study type

Interventional

Funder types

Other

Identifiers

NCT00577642

07-144

ASCO CDA

Details and patient eligibility

About

The purpose of this research study is to define the time a molecule in the participants bones called NTX begins to rise after receiving treatment with bisphosphonates. NTX is measured in the urine to determine the rate of bone breakdown. Tracking this marker may help identify a more optimal dosing schedule of bisphosphonate therapy. Bisphosphonate drugs like zoledronic acid, which will be used in this study, are used to reduce pain and bone fractures in people with multiple myeloma. There is some laboratory data to suggest that they may work against myeloma. Participants will have already undergone bisphosphonate therapy and may have received zoledronic acid as treatment. Typically these agents are continued indefinitely. Due to concerns of their long-term side effects we are looking at alternate strategies for reducing the frequency of these agents.

Full description

Each participant will receive a single dose of zoledronic acid intravenously after the screening procedures.
Participants will then return to the clinic once every month for 6 months and have the following tests and procedures performed: Medical history update; physical exam; ECOG (Eastern Cooperative Oncology Group) Performance Status; blood tests; and urine tests.
After 6 months there will be an end of study visit, where the following procedures will take place: medical history update; bone marrow aspirate and biopsy; skeletal survey.

Enrollment

29 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men or women 18 years of age or older
Confirmed diagnosis of multiple myeloma(MM) by Durie and Dalmon staging criteria on IV bisphosphonate therapy with either pamidronate or zoledronic acid for 8-12 months
MM patients in either CR (complete response) or PR (partial response) by EBMT criteria
ECOG Performance Status of 0-2

Exclusion criteria

MM patients on active anti-MM therapy (maintenance regimens allowed)
Renal failure with serum creatinine >2mg/dL and/or creatinine clearance of <30ml/min
Relapsed, refractory or progressive disease
Any condition or situation that, in the opinion of the investigator, may put the subject at significant risk, confound the results of the study, or interfere significantly with the subject's participation in the study
Hypersensitivity or any contraindication to a single dose of zoledronic acid